The Company approved the grant of 2,450,000 restricted ordinary shares, equivalent to 245,000 ADS to certain directors, officers and employees on November 16, 2009, which was approximately 0.8% of the Company's issued ordinary shares. These restricted ordinary shares vest over a period of three years.
Amortization of acquired intangible assets for 2Q FY2009 was RMB49.8 million (US$7.3 million), of which RMB22.4 million was allocated to cost of revenues and RMB27.4 million to operating expenses.
As of September 30, 2009, the Company's cash and cash equivalents was RMB1,236.7 million (US$181.2 million). Net cash generated from operating activities for 2Q FY2009 was RMB45.5 million (US$6.7 million).
As of September 30, 2009, the Company's net accounts receivable was RMB317.9 million (US$46.6 million), representing a decrease of 7.3% from the balance at March 31, 2009.
For the convenience of readers, certain RMB amounts have been translated into U.S. dollars at the rate of RMB6.8262 to US$1.00, the noon buying rate in New York City for cable transfers of RMB per U.S. dollar as set forth in the H.10 weekly statistical release of the Federal Reserve Board, as of Wednesday, September 30, 2009. No representation is made that the RMB amounts could have been or could be converted into U.S. dollars at that rate or at any other certain rate on September 30, 2009 or at any other dates.
Outlook for 3Q FY2009
Given the full impact of the price reduction on ECLIA reagent kits but
certain positive trends in December quarter, the Company estimates the target
revenues for 3Q FY2009 range from RMB170.0 million (US$24.9 million) to
RMB180.0 million (US$26.4 millio
|SOURCE China Medical Technologies, Inc.|
Copyright©2009 PR Newswire.
All rights reserved